睿知中国疾病研究地图
候选清单0

天津北京协和医学院/中国医学科学院

中国医学科学院血液病医院(血液学研究所)

Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

中国医学科学院血液病医院(血液学研究所)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  2. 多发性骨髓瘤Multiple myeloma47 篇牵头论文牵头 28 项开放试验
  3. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia13 篇牵头论文牵头 12 项开放试验
  4. 再生障碍性贫血Aplastic anaemia48 篇牵头论文牵头 9 项开放试验
  5. β 地中海贫血Beta thalassaemia1 篇牵头论文
  6. 血友病 AHaemophilia A25 篇牵头论文牵头 5 项开放试验
  7. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  8. 范可尼贫血Fanconi anaemia3 篇牵头论文
  9. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  10. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  11. 戈谢病Gaucher disease0 篇牵头论文
  12. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、IgA 肾病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 47 篇,占 2.8%。

牵头论文
47
2021–2025 年
牵头试验
42
任何状态,ClinicalTrials.gov
牵头的开放试验
28
正在或即将招募
作为研究中心的开放试验
24
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 8820222023: 131320232024: 171720242025: 772025

天津有 5 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 52

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07322159

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  2. 正在招募
    MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
    分期
    II期
    开始
    2026-07
    登记号
    NCT07409454

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  3. 正在招募
    CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
    分期
    II期
    开始
    2026-09
    登记号
    NCT07585760

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  4. 正在招募
    CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
    分期
    II期
    开始
    2026-09
    登记号
    NCT07652905

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  5. 正在招募
    BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
    分期
    II期
    开始
    2025-02
    登记号
    NCT06793449

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  6. 正在招募
    Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
    分期
    不分期
    开始
    2025-04
    登记号
    NCT06793475

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  7. 正在招募
    BCMA CAR-T for Dynamic High-risk Multiple Myeloma
    分期
    II期
    开始
    2025-03
    登记号
    NCT06880393

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  8. 正在招募
    A Study of CT0596 in Plasma Cell Leukemia
    分期
    早期I期
    开始
    2025-06
    登记号
    NCT06988059

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  9. 正在招募
    A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
    分期
    II期
    开始
    2025-08
    登记号
    NCT07106671

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  10. 正在招募
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
    分期
    II期
    开始
    2025-08
    登记号
    NCT07106684

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  11. 正在招募
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
    分期
    II期
    开始
    2025-08
    登记号
    NCT07106710

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  12. 正在招募
    MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
    分期
    II期
    开始
    2025-08
    登记号
    NCT07106736

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  13. 正在招募
    Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
    分期
    I/II期
    开始
    2025-03
    登记号
    NCT07109323

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  14. 正在招募
    Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
    分期
    I/II期
    开始
    2025-03
    登记号
    NCT07169500

    年龄 18 岁 至 50 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  15. 正在招募
    CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-03
    登记号
    NCT07249073

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  16. 正在招募
    BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06745687

    年龄 18 岁 至 78 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  17. 正在招募
    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
    分期
    II期
    开始
    2023-08
    登记号
    NCT05979363

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  18. 正在招募
    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
    分期
    II期
    开始
    2023-12
    登记号
    NCT06158269

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  19. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  20. 正在招募
    ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
    分期
    I/II期
    开始
    2022-07
    登记号
    NCT05632380

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  21. 正在招募
    National Longitudinal Cohort of Hematological Diseases
    分期
    未注明
    开始
    2020-12
    登记号
    NCT04645199

    年龄未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  22. 即将招募
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07399444

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州

  23. 即将招募
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
    分期
    早期I期
    开始
    2026-04
    登记号
    NCT07539233

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  24. 即将招募
    Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
    分期
    I/II期
    开始
    2026-08
    登记号
    NCT07687004

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  25. 即将招募
    A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-07
    登记号
    NCT07726160

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  26. 即将招募
    HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    分期
    II期
    开始
    2026-09
    登记号
    NCT07811986

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  27. 即将招募
    CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    分期
    II期
    开始
    2026-10
    登记号
    NCT07830485

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  28. 即将招募
    QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    分期
    II期
    开始
    2026-12
    登记号
    NCT07903636

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  29. 正在招募
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    分期
    I期
    开始
    2026-02
    登记号
    NCT07409246

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心天津、杭州

  30. 正在招募
    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-03
    登记号
    NCT07452198

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  31. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  32. 正在招募
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-03
    登记号
    NCT07529782

    年龄 未注明 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州

  33. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  34. 正在招募
    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-01
    登记号
    NCT07579234

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  35. 正在招募
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    分期
    I期
    开始
    2026-09
    登记号
    NCT07620275

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国人民解放军总医院;另有 2 家列出的医院为研究中心北京、天津

  36. 正在招募
    GR1803 Injection in Patients With RRMM
    分期
    II期
    开始
    2025-04
    登记号
    NCT06952075

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  37. 正在招募
    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07018050

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  38. 正在招募
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    不分期
    开始
    2025-09
    登记号
    NCT07100067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉

  39. 正在招募
    A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2025-07
    登记号
    NCT07312188

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  40. 正在招募
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
    分期
    I/II期
    开始
    2024-02
    登记号
    NCT06232096

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  41. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

  42. 正在招募
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07028970

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州

  43. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  44. 正在招募
    A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05521802

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  45. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  46. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  47. 正在招募
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2021-02
    登记号
    NCT04634552

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安

  48. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  49. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  50. 即将招募
    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-12
    登记号
    NCT07910903

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  51. 即将招募
    Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2025-09
    登记号
    NCT07181239

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  52. 即将招募
    A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-08
    登记号
    NCT06500507

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药干细胞移植
牵头的论文47
  1. Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.2026Advanced materials (Deerfield Beach, Fla.)
  2. Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Prodigiosin inhibits proliferation and induces apoptosis through influencing amino acid metabolism in multiple myeloma.2025Bioorganic chemistry
  4. Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma.2025Blood
  5. Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.2025Cell transplantation免费全文
  6. Identification and transformation of novel targets for immunotherapy in multiple myeloma.2025Chinese medical journal免费全文
  7. Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.2025Haematologica
  8. Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation.2025Science translational medicine
  9. Raman spectroscopy of dried serum for the detection of rapid noninvasive multiple myeloma.2025Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  10. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.2024American journal of hematology免费全文
  11. T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.2024Annals of hematology
  12. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).2024Annals of hematology
  13. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.2024Blood advances免费全文
  14. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.2024Cancer
  15. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.2024Cell metabolism
  16. Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.2024Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
  17. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).2024Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
  18. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.2024EBioMedicine免费全文
  19. B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.2024ESC heart failure免费全文
  20. DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.2024Frontiers in immunology免费全文
  21. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.2024Haematologica免费全文
  22. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.2024Haematologica
  23. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.2024Journal for immunotherapy of cancer免费全文
  24. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.2024Leukemia
  25. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.2024Leukemia免费全文
  26. Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.2024Scientific reports免费全文
  27. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.2023Annals of hematology免费全文
  28. Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.2023British journal of haematology
  29. Immunotherapy for multiple myeloma: new chances and hope.2023Cancer biology & medicine免费全文
  30. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.2023Cancer biology & medicine免费全文
  31. CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.2023Cancer immunology research
  32. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.2023Cancer research communications免费全文
  33. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.2023Chinese medical journal免费全文
  34. Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma.2023Chinese medical journal免费全文
  35. Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment.2023Clinical and translational medicine免费全文
  36. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.2023Clinical lymphoma, myeloma & leukemiaRCT
  37. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  38. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  39. Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.2023Nature communications免费全文
  40. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.2022BMC medicine免费全文
  41. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.2022Blood advances免费全文
  42. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.2022EBioMedicine免费全文
  43. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.2022Frontiers in immunology免费全文
  44. Comparative analysis of three serum-free light-chain detection systems in the diagnosis of multiple myeloma.2022International journal of laboratory hematology
  45. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.2022Journal of immunotherapy (Hagerstown, Md. : 1997)
  46. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.2022Leukemia & lymphoma
  47. Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.2022Nature communications免费全文
中文论文(未计入)17
  1. [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  4. [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  5. [Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening].2023Zhongguo shi yan xue ye xue za zhi
  6. [Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  7. [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  8. [The Clinical Significance of Oligoclonal Bands in Patient with Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  9. [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].2022Zhonghua nei ke za zhi
  10. [Diagnostic and prognostic value of serum miR-19a-3p in patients with multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  11. [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  12. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].2022Zhonghua yi xue za zhi
  13. [Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation].2021Zhongguo shi yan xue ye xue za zhi
  14. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  15. [Clinical Analysis of Patients with MGUS, Primary Light Chain Amyloidosis, Multiple Myeloma or Multiple Myeloma with Concurrent Amyloidosis].2021Zhongguo shi yan xue ye xue za zhi
  16. [Immunoglobulin M multiple myeloma: a six-case report and literature review].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  17. [Progress in clonal evolution of multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)92
  1. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.即将招募NCT07539233牵头方早期I期2026-04 启动
  2. CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment正在招募NCT07585760牵头方II期2026-09 启动
  3. MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma正在招募NCT07409454牵头方II期2026-07 启动
  4. CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia正在招募NCT07652905牵头方II期2026-09 启动
  5. QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease即将招募NCT07903636牵头方II期2026-12 启动
  6. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)即将招募NCT07399444牵头方早期I期2026-01 启动
  7. IASO206 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07322159牵头方早期I期2026-01 启动
  8. CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma即将招募NCT07830485牵头方II期2026-10 启动
  9. Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification即将招募NCT07687004牵头方I/II期2026-08 启动
  10. HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease即将招募NCT07811986牵头方II期2026-09 启动
  11. A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma即将招募NCT07726160牵头方I期2026-07 启动
  12. ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia正在招募NCT07106684牵头方II期2025-08 启动
  13. CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma正在招募NCT07249073牵头方早期I期2025-03 启动
  14. Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM正在招募NCT07109323牵头方I/II期2025-03 启动
  15. A Study of CT0596 in Plasma Cell Leukemia正在招募NCT06988059牵头方早期I期2025-06 启动
  16. MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma正在招募NCT07106736牵头方II期2025-08 启动
  17. ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma正在招募NCT07106710牵头方II期2025-08 启动
  18. BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma正在招募NCT06793449牵头方II期2025-02 启动
  19. Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients正在招募NCT07169500牵头方I/II期2025-03 启动
  20. Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease正在招募NCT06793475牵头方不分期2025-04 启动
  21. A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma正在招募NCT07106671牵头方II期2025-08 启动
  22. BCMA CAR-T for Dynamic High-risk Multiple Myeloma正在招募NCT06880393牵头方II期2025-03 启动
  23. BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma正在招募NCT06745687牵头方不分期2024-12 启动
  24. DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma正在招募NCT06158269牵头方II期2023-12 启动
  25. A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia正在招募NCT05979363牵头方II期2023-08 启动
  26. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma正在招募NCT05294055牵头方II期2022-04 启动
  27. ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)正在招募NCT05632380牵头方I/II期2022-07 启动
  28. National Longitudinal Cohort of Hematological Diseases正在招募NCT04645199牵头方2020-12 启动
  29. A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma进行中,不再招募NCT05860036牵头方II期2023-04 启动
  30. YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma状态不明NCT05913804牵头方I期2023-06 启动
  31. Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma状态不明NCT06302699牵头方2023-05 启动
  32. A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities进行中,不再招募NCT05850286牵头方II期2023-04 启动
  33. A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia进行中,不再招募NCT05870917牵头方II期2023-05 启动
  34. BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT已撤回NCT05846737牵头方II期2023-05 启动
  35. CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma进行中,不再招募NCT07809594牵头方I期2023-07 启动
  36. ctDNA Methylation Sequencing for Myeloma状态不明NCT05578625牵头方2022-08 启动
  37. Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma状态不明NCT05549973牵头方I期2022-09 启动
  38. Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma状态不明NCT05536700牵头方2021-12 启动
  39. A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma已完成NCT04322292牵头方I期2019-09 启动
  40. a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients状态不明NCT04008888牵头方不分期2018-01 启动
  41. Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM状态不明NCT05749133牵头方(推断)I/II期2023-04 启动
  42. Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma状态不明NCT05693012牵头方(推断)2022-08 启动
  43. Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma即将招募NCT07910903研究中心III期2026-12 启动
  44. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  45. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  46. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07529782研究中心I期2026-03 启动
  47. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA正在招募NCT07620275研究中心I期2026-09 启动
  48. A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07579234研究中心III期2026-01 启动
  49. A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07452198研究中心III期2026-03 启动
  50. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)正在招募NCT07409246研究中心I期2026-02 启动
  51. Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients即将招募NCT07181239研究中心III期2025-09 启动
  52. LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07100067研究中心不分期2025-09 启动
  53. Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma正在招募NCT07018050研究中心II期2025-09 启动
  54. A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07312188研究中心II期2025-07 启动
  55. GR1803 Injection in Patients With RRMM正在招募NCT06952075研究中心II期2025-04 启动
  56. A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma即将招募NCT06500507研究中心I期2024-08 启动
  57. A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.正在招募NCT06232096研究中心I/II期2024-02 启动
  58. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  59. Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection正在招募NCT07028970研究中心2024-12 启动
  60. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  61. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  62. A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT05521802研究中心I/II期2022-11 启动
  63. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  64. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  65. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT04634552研究中心II期2021-02 启动
  66. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  67. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06934044研究中心I期2025-05 启动
  68. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  69. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  70. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  71. A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma已终止NCT05590377研究中心I/II期2023-01 启动
  72. A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma状态不明NCT05920876研究中心I期2023-06 启动
  73. Study of 3D189 in Patients With Hematologic Malignancies已完成NCT05320809研究中心I期2022-08 启动
  74. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma已完成NCT05376345研究中心I期2022-09 启动
  75. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  76. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant进行中,不再招募NCT05317416研究中心III期2022-03 启动
  77. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  78. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  79. A Study of TQB3820 in Patients With Hematological Malignancies状态不明NCT05020639研究中心I期2021-08 启动
  80. A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma已完成NCT05011097研究中心I期2021-07 启动
  81. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  82. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  83. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma已完成NCT04121260研究中心I期2019-12 启动
  84. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  85. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  86. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  87. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  88. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  89. Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications已完成NCT02649790研究中心I/II期2016-01 启动
  90. Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma状态不明NCT02916420研究中心III期2016-09 启动
  91. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  92. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma已完成NCT00689936研究中心III期2008-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 13 篇,占 5.8%。

牵头论文
13
2021–2025 年
牵头试验
17
任何状态,ClinicalTrials.gov
牵头的开放试验
12
正在或即将招募
作为研究中心的开放试验
8
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 2220232024: 2220242025: 552025

天津有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 20

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    分期
    I期
    开始
    2025-06
    登记号
    NCT07106749

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  4. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

  5. 正在招募
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    分期
    不分期
    开始
    2024-02
    登记号
    NCT06355739

    年龄 3 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  6. 正在招募
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    分期
    II期
    开始
    2024-04
    登记号
    NCT06387121

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  7. 正在招募
    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
    分期
    不分期
    开始
    2024-06
    登记号
    NCT06481228

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  8. 正在招募
    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
    分期
    不分期
    开始
    2024-06
    登记号
    NCT06481241

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  9. 正在招募
    Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
    分期
    II期
    开始
    2024-08
    登记号
    NCT06608732

    年龄 16 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  10. 即将招募
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    分期
    I期
    开始
    2026-04
    登记号
    NCT07539610

    年龄 18 岁 至 69 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  11. 即将招募
    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
    分期
    II期
    开始
    2026-10
    登记号
    NCT07840976

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  12. 即将招募
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    分期
    I期
    开始
    2025-11
    登记号
    NCT07234045

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  13. 正在招募
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    分期
    I期
    开始
    2026-06
    登记号
    NCT07616089

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  14. 正在招募
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    分期
    I/II期
    开始
    2025-02
    登记号
    NCT06481735

    年龄 16 岁 至 70 岁(登记的条件)

    牵头:中国人民解放军总医院;另有 3 家列出的医院为研究中心北京、天津

  15. 正在招募
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    分期
    早期I期
    开始
    2025-09
    登记号
    NCT07205315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  16. 正在招募
    CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
    分期
    II期
    开始
    2024-01
    登记号
    NCT06179524

    年龄 未注明 至 25 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  17. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  18. 正在招募
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05667506

    年龄 3 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆

  19. 正在招募
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    分期
    II期
    开始
    2022-01
    登记号
    NCT05334823

    年龄 3 岁 至 21 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙

  20. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童费城染色体与遗传学CAR-T 与细胞治疗
牵头的论文13
  1. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.2025Blood advances免费全文
  2. Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.2025Frontiers in immunology免费全文
  3. Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.2025Molecular oncology免费全文
  4. Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.2025Scientific reports免费全文
  5. Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.2025Signal transduction and targeted therapy免费全文
  6. Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.2024Annals of hematology
  7. Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.2024Cancer letters
  8. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.2023British journal of haematology
  9. Functional diversification and dynamics of CAR-T cells in patients with B-ALL.2023Cell reports
  10. Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report.2022Frontiers in immunology免费全文
  11. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.2022Hematology (Amsterdam, Netherlands)
  12. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.2021Blood cancer journal免费全文
  13. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.2021Cancer immunology, immunotherapy : CII免费全文
中文论文(未计入)4
  1. [How I manage relapsed/refractory B-cell acute lymphoblastic leukemia patients treated with CD19 CAR- T cells throughout whole-process management].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [The safety and efficacy of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia in children].2024Zhonghua yi xue za zhi
  3. [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
  4. [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
  1. Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL即将招募NCT07840976牵头方II期2026-10 启动
  2. Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors即将招募NCT07539610牵头方I期2026-04 启动
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol正在招募NCT06764238牵头方II/III期2025-01 启动
  4. Newly-diagnosed Pediatric Ph-positive B-ALL Protocol正在招募NCT07152041牵头方III期2025-03 启动
  5. A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms即将招募NCT07234045牵头方I期2025-11 启动
  6. Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol正在招募NCT06882057牵头方II/III期2025-03 启动
  7. CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies正在招募NCT07106749牵头方I期2025-06 启动
  8. Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.正在招募NCT06608732牵头方II期2024-08 启动
  9. Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL正在招募NCT06387121牵头方II期2024-04 启动
  10. Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL正在招募NCT06481228牵头方不分期2024-06 启动
  11. Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL正在招募NCT06481241牵头方不分期2024-06 启动
  12. A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia已终止NCT05292898牵头方I期2022-03 启动
  13. γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)状态不明NCT04028440牵头方早期I期2019-10 启动
  14. CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)已终止NCT04034446牵头方早期I期2019-09 启动
  15. CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia已完成NCT02975687牵头方I期2016-11 启动
  16. CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+正在招募NCT06355739牵头方(推断)不分期2024-02 启动
  17. Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia状态不明NCT01990807牵头方(推断)IV期2012-10 启动
  18. Phase I Study of FXS0683 in the Treatment of Blood Tumors正在招募NCT07616089研究中心I期2026-06 启动
  19. A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia正在招募NCT07205315研究中心早期I期2025-09 启动
  20. TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL正在招募NCT06481735研究中心I/II期2025-02 启动
  21. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia正在招募NCT06450067研究中心2024-06 启动
  22. CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL正在招募NCT06179524研究中心II期2024-01 启动
  23. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)正在招募NCT05667506研究中心I/II期2023-02 启动
  24. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents正在招募NCT05334823研究中心II期2022-01 启动
  25. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)正在招募NCT05579132研究中心I/II期2022-11 启动
  26. Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)进行中,不再招募NCT06054113研究中心II期2024-07 启动
  27. CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia状态不明NCT05727683研究中心I期2022-04 启动
  28. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  29. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 48 篇,占 11.7%。

牵头论文
48
2021–2025 年
牵头试验
30
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 101020222023: 141420232024: 6620242025: 992025

天津有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
    分期
    未注明
    开始
    2026-02
    登记号
    NCT07461116

    年龄未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  2. 正在招募
    Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
    分期
    I/II期
    开始
    2026-06
    登记号
    NCT07714512

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  3. 正在招募
    Reproductive and Mental Health of Patients With Aplastic Anemia
    分期
    未注明
    开始
    2025-03
    登记号
    NCT06936930

    年龄 18 岁 至 40 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  4. 正在招募
    Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
    分期
    II期
    开始
    2025-02
    登记号
    NCT07010237

    年龄 65 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  5. 正在招募
    The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
    分期
    I/II期
    开始
    2025-12
    登记号
    NCT07287228

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  6. 正在招募
    Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07578675

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  7. 正在招募
    Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
    分期
    II期
    开始
    2023-02
    登记号
    NCT06254560

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  8. 正在招募
    National Longitudinal Cohort of Hematological Diseases
    分期
    未注明
    开始
    2020-12
    登记号
    NCT04645199

    年龄未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  9. 即将招募
    Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
    分期
    II期
    开始
    2025-07
    登记号
    NCT07078721

    年龄 18 岁 至 50 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  10. 即将招募
    Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
    分期
    I/II期
    开始
    2025-03
    登记号
    NCT06791824

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫抑制治疗儿童干细胞移植
论文中的科室儿科
牵头的论文48
  1. Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.2025Annals of hematology免费全文
  2. Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.2025Annals of hematology免费全文
  3. The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.2025Annals of hematology免费全文
  4. Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.2025Blood
  5. Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.2025Cancer immunology, immunotherapy : CII免费全文
  6. Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia.2025European journal of haematology
  7. Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.2025Frontiers in immunology免费全文
  8. Cost utility analysis of adult patients with severe aplastic anemia: a single-center study.2025Hematology (Amsterdam, Netherlands)
  9. Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.2025Journal of thrombosis and haemostasis : JTH
  10. A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses.2024Annals of hematology免费全文
  11. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.2024Bone marrow transplantation免费全文
  12. Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.2024Experimental hematology
  13. Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.2024Frontiers in immunology免费全文
  14. Encephalitozoon hellem infection after haploidentical allogeneic hematopoietic stem cell transplantation in children: a case report.2024Frontiers in immunology免费全文
  15. Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation.2024Scientific reports免费全文
  16. Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.2023American journal of hematology
  17. Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.2023Annals of hematology免费全文
  18. Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.2023BMC medical genomics免费全文
  19. Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis.2023British journal of haematology
  20. Phenotypic and genotypic correlation evaluation of 148 pediatric patients with Fanconi anemia in a Chinese rare disease cohort.2023Clinica chimica acta; international journal of clinical chemistry
  21. Long-term outcomes of aplastic anemia with cytogenetic abnormalities at diagnosis.2023European journal of haematology
  22. Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.2023Frontiers in immunology免费全文
  23. Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia.2023Frontiers in immunology免费全文
  24. Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia.2023Frontiers in immunology免费全文
  25. Interleukin-10 promoter variability is associated with the susceptibility, severity, and clinical outcomes of aplasitc anemia in Han-Chinese population.2023International journal of laboratory hematology
  26. Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia.2023Journal of autoimmunity
  27. Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.2023Scientific reports免费全文
  28. Application of serum Raman spectroscopy in rapid and early discrimination of aplastic anemia and myelodysplastic syndrome.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  29. Impaired immunosuppressive effect of bone marrow mesenchymal stem cell-derived exosomes on T cells in aplastic anemia.2023Stem cell research & therapy免费全文
  30. Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.2022Annals of hematology免费全文
  31. First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.2022Annals of hematology
  32. Leptin-mediated proinflammatory bone marrow environment in acquired aplastic anemia.2022Cytokine
  33. The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study.2022Frontiers in immunology免费全文
  34. Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.2022Frontiers in immunology免费全文
  35. Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors.2022Frontiers in immunology免费全文
  36. Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.2022Frontiers in immunology免费全文
  37. Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.2022Haematologica
  38. Short Stature in Patients with Diamond-Blackfan Anemia: A Cross-Sectional Study.2022The Journal of pediatrics
  39. Efficacy of anti-thymocyte globulin for platelet transfusion refractoriness in serious aplastic anemia patients.2022Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  40. PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis.2021Acta haematologica
  41. Red blood cell lifespan is reduced in severe aplastic anemia and improves with response to immunosuppressive treatment.2021American journal of hematology
  42. Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia.2021Annals of hematology
  43. Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine.2021Annals of hematology
  44. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.2021BMC pediatrics免费全文
  45. Successful Treatment of a 19-Month-Old Boy with Hepatitis Associated Aplastic Anemia by Infusion of Umbilical Cord-Derived Mesenchymal Stromal Cells: A Case Report.2021Cell transplantation免费全文
  46. Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia.2021Chinese medical journal免费全文
  47. Platelet/Lymphocyte ratio independently predicts the outcome of severe aplastic anemia patients treated with antithymocyte globulin.2021Revista da Associacao Medica Brasileira (1992)
  48. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.2021Stem cell research & therapy免费全文
中文论文(未计入)24
  1. [Advancements in CRISPR-Cas9 for Fanconi anemia].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Melatonin-Mediated Inhibitory Effect on Hyperimmune Status of Acquired Aplastic Anemia].2023Zhongguo shi yan xue ye xue za zhi
  3. [Clinical characteristics of aplastic anemia patients with abnormal autoantibodies and the impact of autoantibodies on immunosuppressive therapy response].2023Zhonghua nei ke za zhi
  4. [Evaluation of the clinical manifestations of COVID-19 in patients with aplastic anemia undergoing immunosuppressive therapy: a prospective cohort study (NICHE)].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  5. [Efficacy and safety of allogeneic hematopoietic stem cell transplantation in the treatment of 28 patients with hepatitis-related aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  6. [Metagenomic next-generation sequencing of plasma for the identification of bloodstream infectious pathogens in severe aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  7. [The effect of on-demand glucocorticoid strategy on the occurrence and outcome of p-ALG-associated serum sickness in aplastic anemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  8. [Clinical analysis of 76 patients with severe aplastic anemia treated with haploid hematopoietic stem cell transplantation].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  9. [T-large granular lymphocytic leukemia presenting as aplastic anemia: a report of five cases and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  10. [Prevalence and risk factors of obesity in children with Diamond-Blackfan anemia].2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
  11. Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
  12. [Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  13. [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  14. [Kinetics of immune activated T cells in aplastic anemia mouse model].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  15. [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  16. [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  17. [Bone marrow failure with body deformities].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  18. Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.2021Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
  19. [Clinical Characteristics and Prognosis Analysis of Pediatric Severe Aplastic Anemia].2021Zhongguo shi yan xue ye xue za zhi
  20. [Optimization of Mouse Model of Aplastic Anemia Induced by Pan T Lymphocytes Combined with Irradiation].2021Zhongguo shi yan xue ye xue za zhi
  21. [Relationship between Changes of Lymphocyte Subsets and Early Hematologic Response in Immunosuppressive Therapy of Severe Aplastic Anemia Patients].2021Zhongguo shi yan xue ye xue za zhi
  22. [Advances in bone marrow failure related ribosomopathies].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
  23. [Syngeneic hematopoietic stem cell transplantation for aplastic anemia].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  24. [A real-world study of 176 cases with aplastic anemia treated in outpatient].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)35
  1. Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia正在招募NCT07714512牵头方I/II期2026-06 启动
  2. Adverse Effects of ATG/ALG Therapy in Aplastic Anemia正在招募NCT07461116牵头方2026-02 启动
  3. Reproductive and Mental Health of Patients With Aplastic Anemia正在招募NCT06936930牵头方2025-03 启动
  4. Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS正在招募NCT07578675牵头方2025-10 启动
  5. The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia正在招募NCT07287228牵头方I/II期2025-12 启动
  6. Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia正在招募NCT07010237牵头方II期2025-02 启动
  7. Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia即将招募NCT07078721牵头方II期2025-07 启动
  8. Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness正在招募NCT06254560牵头方II期2023-02 启动
  9. National Longitudinal Cohort of Hematological Diseases正在招募NCT04645199牵头方2020-12 启动
  10. CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia已暂停NCT06622694牵头方I期2025-06 启动
  11. Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia进行中,不再招募NCT06613880牵头方II期2024-10 启动
  12. Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia已终止NCT06695741牵头方II期2024-11 启动
  13. Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia状态不明NCT05975996牵头方II期2023-07 启动
  14. Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia已完成NCT05832216牵头方I期2023-04 启动
  15. Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function状态不明NCT05571332牵头方不分期2022-06 启动
  16. Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly状态不明NCT05433922牵头方不分期2022-06 启动
  17. The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA状态不明NCT05518331牵头方不分期2022-06 启动
  18. A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency状态不明NCT05531279牵头方不分期2022-06 启动
  19. Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia已完成NCT05660785牵头方II期2022-12 启动
  20. Avatrombopag Combined With IST as First-line Treatment for SAA状态不明NCT05720234牵头方II期2022-11 启动
  21. Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA已完成NCT07850362牵头方不分期2021-09 启动
  22. Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia已终止NCT04854889牵头方II期2021-04 启动
  23. A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic Anemia已完成NCT07903649牵头方II期2021-02 启动
  24. A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia已完成NCT02203396牵头方II期2014-08 启动
  25. Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)状态不明NCT01760096牵头方II期2013-01 启动
  26. Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria状态不明NCT01642979牵头方II期2012-07 启动
  27. Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)状态不明NCT02218437牵头方(推断)IV期2013-10 启动
  28. Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia状态不明NCT01995331牵头方(推断)IV期2012-03 启动
  29. Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia状态不明NCT01997372牵头方(推断)IV期2010-12 启动
  30. Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their PatentsAvailableNCT01995305牵头方(推断)
  31. Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia即将招募NCT06791824研究中心I/II期2025-03 启动
  32. Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia状态不明NCT05797623研究中心II期2023-04 启动
  33. Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia已完成NCT03825744研究中心III期2019-03 启动
  34. Extension Study of Hetrombopag in Severe Aplastic Anemia状态不明NCT04961710研究中心III期2019-09 启动
  35. A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient已完成NCT03557099研究中心I/II期2018-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

天津有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    β-Thalassemia Treatment With KL003 Cell Injection
    分期
    I/II期
    开始
    2024-04
    登记号
    NCT06280378

    年龄 3 岁 至 35 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 25 篇,占 9.2%。

牵头论文
25
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 7720222023: 6620232024: 3320242025: 552025

天津有 1 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
    分期
    早期I期
    开始
    2024-01
    登记号
    NCT06238908

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  2. 正在招募
    ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
    分期
    IV期
    开始
    2023-11
    登记号
    NCT05888870

    年龄 14 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  3. 正在招募
    A Study of FVIII Gene Therapy for Hemophilia A
    分期
    早期I期
    开始
    2022-07
    登记号
    NCT05454774

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  4. 正在招募
    Gene Therapy for Chinese Hemophilia A
    分期
    不分期
    开始
    2021-03
    登记号
    NCT04728841

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  5. 正在招募
    National Longitudinal Cohort of Hematological Diseases
    分期
    未注明
    开始
    2020-12
    登记号
    NCT04645199

    年龄未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所)天津

  6. 正在招募
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    分期
    III期
    开始
    2026-04
    登记号
    NCT07416604

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、广州、福州

  7. 正在招募
    Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
    分期
    III期
    开始
    2026-03
    登记号
    NCT07545395

    年龄 12 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

  8. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

  9. 正在招募
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    分期
    II/III期
    开始
    2024-01
    登记号
    NCT06111638

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙

  10. 正在招募
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    分期
    III期
    开始
    2022-12
    登记号
    NCT05611801

    年龄 1 岁 至 17 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉

  11. 正在招募
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    分期
    III期
    开始
    2021-11
    登记号
    NCT05145127

    年龄 1 岁 至 74 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、广州、武汉、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文25
  1. Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.2025Advances in therapy
  2. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  3. Nationwide Survey of Laboratory Practices for Factor VIII Inhibitor Detection in China.2025Haemophilia : the official journal of the World Federation of Hemophilia
  4. The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.2025Hematology (Amsterdam, Netherlands)
  5. Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A.2025Journal of controlled release : official journal of the Controlled Release Society
  6. Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.2024American journal of hematologyRCT
  7. Decoding the complexity of on-target integration: characterizing DNA insertions at the CRISPR-Cas9 targeted locus using nanopore sequencing.2024BMC genomics
  8. Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.2024Haemophilia : the official journal of the World Federation of Hemophilia
  9. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.2023Haemophilia : the official journal of the World Federation of Hemophilia
  10. Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.2023Haemophilia : the official journal of the World Federation of Hemophilia
  11. Women and girls with haemophilia: A retrospective cohort study in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  12. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  13. Anti-CD38 antibody for refractory acquired hemophilia A.2023Journal of thrombosis and haemostasis : JTH
  14. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.2023Journal of thrombosis and haemostasis : JTH
  15. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.2022Haemophilia : the official journal of the World Federation of HemophiliaRCT
  16. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.2022Haemophilia : the official journal of the World Federation of Hemophilia
  17. Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population.2022Haemophilia : the official journal of the World Federation of Hemophilia
  18. Haemophilia gene therapy-Update on new country initiatives.2022Haemophilia : the official journal of the World Federation of Hemophilia
  19. Demographics, clinical profile and treatment landscape of patients with haemophilia B in China.2022Haemophilia : the official journal of the World Federation of Hemophilia
  20. Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.2022Human gene therapy
  21. Total Knee Arthroplasty after Gene Therapy for Hemophilia B.2022The New England journal of medicine
  22. Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.2021British journal of haematology
  23. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up.2021British journal of haematology
  24. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  25. An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies.2021Haemophilia : the official journal of the World Federation of Hemophilia
中文论文(未计入)5
  1. [How I treat acquired clotting factor deficiency].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. [Keeping up with the trends and improving the hierarchical system for the diagnosis and treatment of hemophilia in China].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Recent advances in the replacement therapy for Hemophilia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
早期论文(2016–2020 年)19
  1. Growing success and ambitions of the Chinese edition of Haemophilia.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Haemophilia care in China: Achievements in the past decade.2020Haemophilia : the official journal of the World Federation of Hemophilia
  4. Real-world analysis of haemophilia patients in China: A single centre's experience.2020Haemophilia : the official journal of the World Federation of Hemophilia
  5. Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.2019Blood advances
  6. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.2019British journal of haematology
  7. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.2019Genome biology
  8. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.2019Haemophilia : the official journal of the World Federation of Hemophilia
  9. [How I treat hemophilia with inhibitors].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  10. [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  11. [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  12. [Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  13. Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.2017Scientific reports
  14. [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  15. [Advances in Hemophilia A inhibitors].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  16. [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  17. [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  18. Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.2016Haemophilia : the official journal of the World Federation of Hemophilia
  19. [Study on risk factors and follow-up of 26 hemophilia A children with inhibitors].2016Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)47
  1. Safety and Efficacy Study of NGGT003 in Hemophilia A Patients正在招募NCT06238908牵头方早期I期2024-01 启动
  2. ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor正在招募NCT05888870牵头方IV期2023-11 启动
  3. A Study of FVIII Gene Therapy for Hemophilia A正在招募NCT05454774牵头方早期I期2022-07 启动
  4. Gene Therapy for Chinese Hemophilia A正在招募NCT04728841牵头方不分期2021-03 启动
  5. National Longitudinal Cohort of Hematological Diseases正在招募NCT04645199牵头方2020-12 启动
  6. A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A即将招募NCT07788469牵头方不分期2026-10 启动
  7. The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.状态不明NCT05523128牵头方不分期2022-09 启动
  8. Data Registry in Chinese Hemophilia A and B Patients已完成NCT07101224牵头方2017-05 启动
  9. Safety of KN057 Prophylaxis in Patients With Haemophilia A or B正在招募NCT07545395研究中心III期2026-03 启动
  10. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A正在招募NCT07416604研究中心III期2026-04 启动
  11. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  12. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs正在招募NCT06111638研究中心II/III期2024-01 启动
  13. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B正在招募NCT05611801研究中心III期2022-12 启动
  14. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors正在招募NCT05145127研究中心III期2021-11 启动
  15. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  16. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  17. Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors进行中,不再招募NCT06312475研究中心III期2024-01 启动
  18. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A进行中,不再招募NCT06297655研究中心III期2024-11 启动
  19. Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors进行中,不再招募NCT06569108研究中心III期2024-04 启动
  20. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency正在招募NCT07644832研究中心I/II期2024-05 启动
  21. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  22. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  23. SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment已完成NCT06010953研究中心I/II期2023-10 启动
  24. To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A进行中,不再招募NCT07548411研究中心I/II期2023-07 启动
  25. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  26. A Phase I of SS109 in Hemophilia A or and B With Inhibitors已完成NCT05651061研究中心I期2022-12 启动
  27. A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection已完成NCT05265286研究中心II期2022-04 启动
  28. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor状态不明NCT05487976研究中心III期2022-04 启动
  29. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors已完成NCT05306418研究中心III期2022-04 启动
  30. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  31. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  32. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection已完成NCT04864743研究中心I期2021-06 启动
  33. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  34. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B已完成NCT03938792研究中心III期2020-03 启动
  35. A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor已完成NCT04747964研究中心I期2020-01 启动
  36. Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.状态不明NCT04768699研究中心I期2020-12 启动
  37. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  38. Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.状态不明NCT03947567研究中心IV期2019-07 启动
  39. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection状态不明NCT03747653研究中心2019-03 启动
  40. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  41. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04060836研究中心I期2019-05 启动
  42. Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A已完成NCT03815318研究中心III期2019-01 启动
  43. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants已完成NCT03315455研究中心III期2018-04 启动
  44. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A状态不明NCT02930317研究中心III期2016-08 启动
  45. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  46. A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment已完成NCT02476942研究中心2015-05 启动
  47. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)已完成NCT02078427研究中心2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. [Clinical characteristics of 83 patients with thrombotic thrombocytopenic purpura].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Advances in the treatment of thrombotic thrombocytopenic purpura].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.4%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

天津有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

天津有 5 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
牵头的论文1
  1. Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis.2025Nature neuroscience
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)邀请入组NCT07539662牵头方不分期2025-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

天津有 3 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06818838

    年龄 18 岁 至 60 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心天津、太原、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinical features and genetic manifestations of two families with Gaucher's disease].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease正在招募NCT06818838研究中心I/II期2024-07 启动
  2. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease已完成NCT05529992研究中心III期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中国医学科学院血液病医院(血液学研究所)

Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

天津

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Yunnan Blood Disease Hospital; Insitute of Hematology & Blood Disarses Hospital; Blood Disease Hospital; Blood Diseases Hospital; Hematology and Blood Diseases Hospital; Institute of Hematology & Blood Diseases Hospital; Institute of Hematology and Blood Diseases Hospital; 中国医学科学院血液病医院

提出更正下载数据